Abstract

A large proportion of colorectal carcinomas (CRC) evolve from colorectal adenomas. However, not all individuals with colonic adenomas have a risk of CRC substantially higher than those of the general population. The aim of the study was to determine the differences or similarities of mutation profile among low- and high-grade adenomas and in situ carcinoma with detailed follow up. We have investigated the mutation spectrum of well-known genes involved in CRC (such as APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53) in a large, well-defined series of 96 adenomas and in situ carcinomas using a high-throughput genotyping technique. Besides, the microsatellite instability and APC and MLH1 promoter methylation were studied as well. We observed a high frequency of pathogenic variants in the studied genes. The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples. Further, when we stratified mutation frequency based on the grade, the frequency distribution was as follows: low-grade adenoma—high-grade adenomas—in situ carcinoma: APC gene 42.9–56.0–54.5%; KRAS gene 32.7–32.0–45.5%; TP53 gene 8.2–20.0–18.2%. The occurrence of KRAS mutation was associated with the presence of villous histology and methylation of the APC promoter was significantly associated with the presence of POLE genetic variations. However, no association was noticed with the presence of any singular mutation and occurrence of subsequent adenoma or CRC. Our data supports the multistep model of gradual accumulation of mutations, especially in the driver genes, such as APC, TP53 and KRAS.

Details

Title
Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition
Author
Jungwirth, Jiri 1 ; Urbanova, Marketa 2 ; Boot, Arnoud 3 ; Hosek, Petr 4 ; Bendova, Petra 5 ; Siskova, Anna 2 ; Svec, Jiri 6 ; Kment, Milan 7 ; Tumova, Daniela 8 ; Summerova, Sandra 9 ; Benes, Zdenek 9 ; Buchler, Tomas 10 ; Kohout, Pavel 9 ; Hucl, Tomas 11 ; Matej, Radoslav 12 ; Vodickova, Ludmila 13 ; van Wezel, Tom 3 ; Vodicka, Pavel 13 ; Vymetalkova, Veronika 13 

 Charles University, Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Prague, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X); Weiden Clinic, Department of Surgery, Weiden in der Oberpfalz, Germany (GRID:grid.4491.8) 
 Charles University, Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Prague, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X); Institute of Experimental Medicine of the Czech Academy of Sciences, Department of Molecular Biology of Cancer, Prague, Czech Republic (GRID:grid.424967.a) (ISNI:0000 0004 0404 6946) 
 Leiden University Medical Center, Department of Pathology, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
 Charles University, Biomedical Center, Faculty of Medicine in Pilsen, Pilsen, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X) 
 Institute of Experimental Medicine of the Czech Academy of Sciences, Department of Molecular Biology of Cancer, Prague, Czech Republic (GRID:grid.424967.a) (ISNI:0000 0004 0404 6946); Charles University, Biomedical Center, Faculty of Medicine in Pilsen, Pilsen, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X) 
 Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic (GRID:grid.418827.0) (ISNI:0000 0004 0620 870X); Charles University, Department of Radiotherapy and Oncology, Third Faculty of Medicine, Prague 10, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X) 
 Charles University, Second Department of Internal Medicine, Third Faculty of Medicine, Prague 10, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X) 
 DT Gastroenterology, Prague 4, Czech Republic (GRID:grid.4491.8) 
 Third Faculty of Medicine Charles University and Thomayer University Hospital, Department of Internal Medicine, Prague, Czech Republic (GRID:grid.448223.b) (ISNI:0000 0004 0608 6888) 
10  Charles University and Thomayer University Hospital, Department of Oncology, First Faculty of Medicine, Prague, Czech Republic (GRID:grid.448223.b) (ISNI:0000 0004 0608 6888) 
11  Institute for Clinical and Experimental Medicine, Department of Hepatogastroenterology, Prague, Czech Republic (GRID:grid.418930.7) (ISNI:0000 0001 2299 1368) 
12  Charles University and Thomayer University Hospital, Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Prague, Czech Republic (GRID:grid.448223.b) (ISNI:0000 0004 0608 6888); Charles University and University Hospital Kralovske Vinohrady, Department of Pathology, Third Faculty of Medicine, Prague 10, Czech Republic (GRID:grid.412819.7) (ISNI:0000 0004 0611 1895) 
13  Charles University, Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Prague, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X); Institute of Experimental Medicine of the Czech Academy of Sciences, Department of Molecular Biology of Cancer, Prague, Czech Republic (GRID:grid.424967.a) (ISNI:0000 0004 0404 6946); Charles University, Biomedical Center, Faculty of Medicine in Pilsen, Pilsen, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2629162797
Copyright
© The Author(s) 2022. corrected publication 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.